
BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
pharmafile | November 27, 2018 | News story | Manufacturing and Production, Research and Development | Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage small cell lung cancer (SCLC) without disease progression following the completion of first-line platinum-based chemotherapy.
Compared to placebo, the manufacturer said that its PD-1 inhibitor/CTLA-4 inhibitor combo failed to improve the Phase 3 trial’s primary endpoint of overall survival compared to placebo. It is not known whether the therapy managed to meet its secondary endpoint of overall survival improvement for Opdivo as a monotherapy.
News of the failure send shares falling by 4%. BMS said that it would be working with investigators on the study to ensure the publication of full results from the study.
Matt Fellows
Related Content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …





